Iceland· IS-EU/1/17/1250/001
Rubraca
A rucaparib product containing rucaparibum inn camsylat, registered in Iceland by Pharmaand GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Rucaparib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XK03 (rucaparib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Rucaparib · ATC L01XK03
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of rucaparib costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rucaparib · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$240.27
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Rucaparibum INN camsylat
- Manufacturer
- Pharmaand GmbH
- Country
- Iceland (IS)
- ATC code
- L01XK03
- ATC class
- Rucaparib
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
692 interactions on record for rucaparib.
Graded by severity as the source publishes them — 103 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rucaparib · interactions on record
692 records
- 103 severe
- 576 moderate
- 13 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XK03
Rucaparib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3295dbdf-635d-4dbc-a6eb-21c9624b71b3 GET /v1/drugs/3295dbdf-635d-4dbc-a6eb-21c9624b71b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01XK03",
"marketed": false,
"strength": "200 mg",
"ma_number": "EU/1/17/1250/001",
"substance": "Rucaparibum INN camsylat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43244"
}See everything about rucaparib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.